Skip to content

A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants from Jasper-Sponsored Chronic Urticaria Trials

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-517830-17-00
Acronym
JSP-CP-014
Enrollment
45
Registered
2025-02-07
Start date
2025-03-14
Completion date
Unknown
Last updated
2025-12-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Urticaria

Brief summary

Incidence and severity of adverse events (AEs) including serious adverse events (SAEs), treatment-emergent adverse events (TEAEs) and adverse events of interest (AEIs). Physical examination findings and standard clinical laboratory parameters.

Detailed description

Chronic inducible urticaria {CIndU}: - Change from baseline in critical temperature threshold (CCT) and critical friction threshold (CFT) over time. - Change from Baseline in urticaria control test (UCT) over time. - Percentage of participants with complete response and well-controlled disease over time., Chronic spontaneous urticaria {CSU}: - Change from baseline in urticaria activity score over 7 days (UAS7), hive severity score over 7 days (HSS7), itch severity score over 7 days (ISS7), and uricaria control test (UCT) over time. - Percentage of participants with complete response and well-controlled disease over time.

Interventions

Sponsors

Jasper Therapeutics Inc.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Incidence and severity of adverse events (AEs) including serious adverse events (SAEs), treatment-emergent adverse events (TEAEs) and adverse events of interest (AEIs). Physical examination findings and standard clinical laboratory parameters.

Secondary

MeasureTime frame
Chronic inducible urticaria {CIndU}: - Change from baseline in critical temperature threshold (CCT) and critical friction threshold (CFT) over time. - Change from Baseline in urticaria control test (UCT) over time. - Percentage of participants with complete response and well-controlled disease over time., Chronic spontaneous urticaria {CSU}: - Change from baseline in urticaria activity score over 7 days (UAS7), hive severity score over 7 days (HSS7), itch severity score over 7 days (ISS7), and uricaria control test (UCT) over time. - Percentage of participants with complete response and well-controlled disease over time.

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026